Keya Medical Covers Technology Advancements and AI Integration at SCCT 2023: A Look at Exceptional Collaborations.
In the dynamic landscape of medical innovation, SCCT 2023 served as an exceptional platform for exchanging cutting-edge insights and breakthroughs in cardiovascular technology.
Clinical Validation of DEEPVESSEL® FFR: AI CT-FFR Analysis by Keya Medical
The ADAPT Study: Assessment of the DiAgnostic Performance of DeepVessel FFR in SuspecTed Coronary Artery Disease SUMMARY DEEPVESSEL FFR is a medical device that is designed to extract three- dimensional coronary tree structures and generate computed tomography-derived...TARGET Randomized On-Site CT FFR Trial Results
New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
Keya Medical’s CT FFR analysis DEEPVESSEL® is now available in the USA.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
Recent Comments